Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015

Jin Hee Kim, Hyo Jin Eom, Gyu Tae Lim, Sungjin Park, Jinhyuk Lee, Seungyoon Nam, Yon Hui Kim, Jin Hyun Jeong

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Gastric cancer (GC) is a highly heterogeneous disease with few “targeted” therapeutic options. Previously, we demonstrated involvement of the transcription factor HNF4α in human GC tumours, and the developmental signal mediator, WNT5A, as a prognostic GC biomarker. One previously developed HNF4α antagonist, BI6015, while not advancing beyond preclinical stages, remains useful for studying GC. Methods: Here, we characterised the antineoplastic signalling activity of derivatives of BI6015, including transfer of the nitro group from the para position, relative to a methyl group on its benzene ring, to the ortho- and meta positions. We assessed binding efficacy, through surface plasmon resonance and docking studies, while biologic activity was assessed by antimitogenic efficacy against a panel of GC cell lines, and dysregulated transcriptomes, followed by pathway and subpathway analysis. Results: The para derivative of BI6105 was found substantially more growth inhibitory, and effective, in downregulating numerous oncogenic signal pathways, including the embryonic cascade WNT. The ortho and meta derivatives, however, failed to downregulate WNT or other embryonic signalling pathways, unable to suppress GC growth. Conclusion: Straightforward strategies, employing bioinformatics analyses, to facilitate the effective design and development of “druggable” transcription factor inhibitors, are useful for targeting specific oncogenic signalling pathways, in GC and other cancers.

Original languageEnglish
Pages (from-to)488-498
Number of pages11
JournalBritish journal of cancer
Volume120
Issue number5
DOIs
Publication statusPublished - 2019 Mar 5

Fingerprint

Stomach Neoplasms
Hepatocyte Nuclear Factor 4
Down-Regulation
Surface Plasmon Resonance
Tumor Biomarkers
Growth
2-methyl-1-(2-methyl-5-nitrophenylsulfonyl)-1H-benzo(d)imidazole
Benzene
Computational Biology
Transcriptome
Antineoplastic Agents
Signal Transduction
Neoplasms
Transcription Factors
Cell Line

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kim, Jin Hee ; Eom, Hyo Jin ; Lim, Gyu Tae ; Park, Sungjin ; Lee, Jinhyuk ; Nam, Seungyoon ; Kim, Yon Hui ; Jeong, Jin Hyun. / Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015. In: British journal of cancer. 2019 ; Vol. 120, No. 5. pp. 488-498.
@article{56c6be9ac9a444da9bd51a71818b557c,
title = "Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015",
abstract = "Background: Gastric cancer (GC) is a highly heterogeneous disease with few “targeted” therapeutic options. Previously, we demonstrated involvement of the transcription factor HNF4α in human GC tumours, and the developmental signal mediator, WNT5A, as a prognostic GC biomarker. One previously developed HNF4α antagonist, BI6015, while not advancing beyond preclinical stages, remains useful for studying GC. Methods: Here, we characterised the antineoplastic signalling activity of derivatives of BI6015, including transfer of the nitro group from the para position, relative to a methyl group on its benzene ring, to the ortho- and meta positions. We assessed binding efficacy, through surface plasmon resonance and docking studies, while biologic activity was assessed by antimitogenic efficacy against a panel of GC cell lines, and dysregulated transcriptomes, followed by pathway and subpathway analysis. Results: The para derivative of BI6105 was found substantially more growth inhibitory, and effective, in downregulating numerous oncogenic signal pathways, including the embryonic cascade WNT. The ortho and meta derivatives, however, failed to downregulate WNT or other embryonic signalling pathways, unable to suppress GC growth. Conclusion: Straightforward strategies, employing bioinformatics analyses, to facilitate the effective design and development of “druggable” transcription factor inhibitors, are useful for targeting specific oncogenic signalling pathways, in GC and other cancers.",
author = "Kim, {Jin Hee} and Eom, {Hyo Jin} and Lim, {Gyu Tae} and Sungjin Park and Jinhyuk Lee and Seungyoon Nam and Kim, {Yon Hui} and Jeong, {Jin Hyun}",
year = "2019",
month = "3",
day = "5",
doi = "10.1038/s41416-018-0374-5",
language = "English",
volume = "120",
pages = "488--498",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "5",

}

Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015. / Kim, Jin Hee; Eom, Hyo Jin; Lim, Gyu Tae; Park, Sungjin; Lee, Jinhyuk; Nam, Seungyoon; Kim, Yon Hui; Jeong, Jin Hyun.

In: British journal of cancer, Vol. 120, No. 5, 05.03.2019, p. 488-498.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Differential effects, on oncogenic pathway signalling, by derivatives of the HNF4 α inhibitor BI6015

AU - Kim, Jin Hee

AU - Eom, Hyo Jin

AU - Lim, Gyu Tae

AU - Park, Sungjin

AU - Lee, Jinhyuk

AU - Nam, Seungyoon

AU - Kim, Yon Hui

AU - Jeong, Jin Hyun

PY - 2019/3/5

Y1 - 2019/3/5

N2 - Background: Gastric cancer (GC) is a highly heterogeneous disease with few “targeted” therapeutic options. Previously, we demonstrated involvement of the transcription factor HNF4α in human GC tumours, and the developmental signal mediator, WNT5A, as a prognostic GC biomarker. One previously developed HNF4α antagonist, BI6015, while not advancing beyond preclinical stages, remains useful for studying GC. Methods: Here, we characterised the antineoplastic signalling activity of derivatives of BI6015, including transfer of the nitro group from the para position, relative to a methyl group on its benzene ring, to the ortho- and meta positions. We assessed binding efficacy, through surface plasmon resonance and docking studies, while biologic activity was assessed by antimitogenic efficacy against a panel of GC cell lines, and dysregulated transcriptomes, followed by pathway and subpathway analysis. Results: The para derivative of BI6105 was found substantially more growth inhibitory, and effective, in downregulating numerous oncogenic signal pathways, including the embryonic cascade WNT. The ortho and meta derivatives, however, failed to downregulate WNT or other embryonic signalling pathways, unable to suppress GC growth. Conclusion: Straightforward strategies, employing bioinformatics analyses, to facilitate the effective design and development of “druggable” transcription factor inhibitors, are useful for targeting specific oncogenic signalling pathways, in GC and other cancers.

AB - Background: Gastric cancer (GC) is a highly heterogeneous disease with few “targeted” therapeutic options. Previously, we demonstrated involvement of the transcription factor HNF4α in human GC tumours, and the developmental signal mediator, WNT5A, as a prognostic GC biomarker. One previously developed HNF4α antagonist, BI6015, while not advancing beyond preclinical stages, remains useful for studying GC. Methods: Here, we characterised the antineoplastic signalling activity of derivatives of BI6015, including transfer of the nitro group from the para position, relative to a methyl group on its benzene ring, to the ortho- and meta positions. We assessed binding efficacy, through surface plasmon resonance and docking studies, while biologic activity was assessed by antimitogenic efficacy against a panel of GC cell lines, and dysregulated transcriptomes, followed by pathway and subpathway analysis. Results: The para derivative of BI6105 was found substantially more growth inhibitory, and effective, in downregulating numerous oncogenic signal pathways, including the embryonic cascade WNT. The ortho and meta derivatives, however, failed to downregulate WNT or other embryonic signalling pathways, unable to suppress GC growth. Conclusion: Straightforward strategies, employing bioinformatics analyses, to facilitate the effective design and development of “druggable” transcription factor inhibitors, are useful for targeting specific oncogenic signalling pathways, in GC and other cancers.

UR - http://www.scopus.com/inward/record.url?scp=85062585496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062585496&partnerID=8YFLogxK

U2 - 10.1038/s41416-018-0374-5

DO - 10.1038/s41416-018-0374-5

M3 - Article

C2 - 30792535

AN - SCOPUS:85062585496

VL - 120

SP - 488

EP - 498

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 5

ER -